Peptide Encyclopedia / Semaglutide + Cagrilintide
EncyclopediaCagriSema is a fixed-dose combination of semaglutide, a GLP-1 receptor agonist, and cagrilintide, a long-acting amylin analog, pairing two appetite pathways to raise satiety and drive weight loss. The combination sits in Phase 3 trials and holds no approval as a single product. Educational only, not medical advice.
| Category | GLP-1 / Metabolic |
| Regulatory status | Investigational combination; not FDA-approved. |
A fixed-dose combination of semaglutide (GLP-1 receptor agonist) and cagrilintide (long-acting amylin analog). The two complementary appetite-regulating pathways aim to enhance satiety, reduce food intake, and improve glycemia/weight loss beyond either alone.
Both components are long-acting (semaglutide roughly 7 days); engineered for once-weekly subcutaneous dosing. Commonly reported use/dosing: No approved protocol. In trials given as once-weekly subcutaneous injection with titration; investigational and not a validated/prescribable regimen.
Investigational combination; not FDA-approved. Developed by Novo Nordisk for obesity/type 2 diabetes (Phase 3, e.g., REDEFINE program). The blend is not approved by any regulator.
GI effects (nausea, vomiting, diarrhea, constipation), decreased appetite; class concerns include pancreatitis, gallbladder disease, and (for GLP-1 agonists) a boxed thyroid C-cell tumor warning in rodents. Long-term combination safety not established.
Phase 3 clinical development; not approved as a combination product.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Semaglutide + Cagrilintide may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
